Breckenridge Pharmaceutical Inc, a US subsidiary of Japan-based Towa Pharmaceutical, announced on Friday that it has signed a multi-product agreement with Germany-based Welding GmbH & Co.
According to the contract, Welding GmbH & Co will develop, manufacture and provide pharmaceutical products for marketing, sale and distribution by the company.
Tthe contact currently covers one delayed release tablet product and two injectable products. Breckenridge has submitted one ANDA to the United States Food and Drug Administration (FDA), one ANDA is likely to be submitted to the FDA this month and one ANDA is in an advanced stage of development.
According to industry sales data, the brand and generics of these three products had annual sales of USD300m during the twelve months ending April 2021.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream